BSD SCIENCE

Company Overview

Snapshot

Founded in January 2022 by Yochai Yakovson, BSD SCIENCE operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on advancing its oral drug delivery system. In 2022, BSD SCIENCE successfully completed a POC PK animal study, achieving promising results that validate its core technology.

Business overview

BSD SCIENCE is a biotech company specializing in the development of an oral dosage form for the controlled release of lipophilic drugs. This innovative platform aims to extend the duration of drug effects, minimize adverse reactions, and improve patient compliance. The technology is applicable across various markets, including medical cannabis, the broader pharmaceutical industry, and dietary supplements, positioning BSD SCIENCE within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drug Delivery.

Company Intelligence Q&A

What is BSD SCIENCE's primary focus?

BSD SCIENCE is focused on developing a unique oral dosage form for the controlled release of lipophilic drugs, aiming for longer efficacy, fewer side effects, and better patient adherence.

When was BSD SCIENCE founded?

BSD SCIENCE was founded in January 2022.

Who is the founder of BSD SCIENCE?

Yochai Yakovson is the Founder & CEO of BSD SCIENCE.

What markets does BSD SCIENCE's platform address?

The platform developed by BSD SCIENCE is suitable for lipophilic molecules used in the Medical Cannabis, Pharma industry, and Dietary Supplement markets.

What significant milestone did BSD SCIENCE achieve in 2022?

In 2022, BSD SCIENCE completed a POC PK animal study, which yielded promising results for its oral drug delivery system, and submitted a U.S. Provisional Patent Application.